These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8005022)

  • 1. Valproic acid-induced neural tube defects.
    Nau H
    Ciba Found Symp; 1994; 181():144-52; discussion 152-60. PubMed ID: 8005022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms.
    Nau H; Hauck RS; Ehlers K
    Pharmacol Toxicol; 1991 Nov; 69(5):310-21. PubMed ID: 1803343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproic acid-induced spina bifida: a mouse model.
    Ehlers K; Stürje H; Merker HJ; Nau H
    Teratology; 1992 Feb; 45(2):145-54. PubMed ID: 1377411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spina bifida aperta induced by valproic acid and by all-trans-retinoic acid in the mouse: distinct differences in morphology and periods of sensitivity.
    Ehlers K; Stürje H; Merker HJ; Nau H
    Teratology; 1992 Aug; 46(2):117-30. PubMed ID: 1440416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methionine reduces the valproic acid-induced spina bifida rate in mice without altering valproic acid kinetics.
    Ehlers K; Elmazar MM; Nau H
    J Nutr; 1996 Jan; 126(1):67-75. PubMed ID: 8558327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The valproic acid metabolite E-2-n-propyl-2-pentenoic acid does not induce spina bifida in the mouse.
    Ehlers K; Stürje H; Merker HJ; Nau H
    Dev Pharmacol Ther; 1992; 19(4):196-204. PubMed ID: 1343622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation.
    Padmanabhan R; Shafiullah MM
    Congenit Anom (Kyoto); 2003 Mar; 43(1):29-40. PubMed ID: 12692401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid.
    Hauck RS; Nau H
    Toxicol Lett; 1989 Oct; 49(1):41-8. PubMed ID: 2510370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis.
    Wegner C; Nau H
    Neurology; 1992 Apr; 42(4 Suppl 5):17-24. PubMed ID: 1574172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolite profiling of whole murine embryos reveals metabolic perturbations associated with maternal valproate-induced neural tube closure defects.
    Akimova D; Wlodarczyk BJ; Lin Y; Ross ME; Finnell RH; Chen Q; Gross SS
    Birth Defects Res; 2017 Jan; 109(2):106-119. PubMed ID: 27860192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxamic acid and fluorinated derivatives of valproic acid: anticonvulsant activity, neurotoxicity and teratogenicity.
    Gravemann U; Volland J; Nau H
    Neurotoxicol Teratol; 2008; 30(5):390-4. PubMed ID: 18455366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New animal model for the study of neural tube defects.
    Michejda M; McCollough D
    Z Kinderchir; 1987 Dec; 42 Suppl 1():32-5. PubMed ID: 3124366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice.
    Nau H; Löscher W
    Fundam Appl Toxicol; 1986 May; 6(4):669-76. PubMed ID: 3086174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
    Ornoy A
    Reprod Toxicol; 2009 Jul; 28(1):1-10. PubMed ID: 19490988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of maternal exposure to homocystine on sodium valproate-induced neural tube defects in the mouse embryos.
    Padmanabhan R; Shafiullah M; Benedict S; Nagelkerke N
    Eur J Nutr; 2006 Sep; 45(6):311-9. PubMed ID: 16699836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimethoprim potentiates valproic acid-induced neural tube defects (NTDs) in mice.
    Elmazar MM; Nau H
    Reprod Toxicol; 1993; 7(3):249-54. PubMed ID: 8318756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid effect on neural tube defects is not prevented by concomitant folic acid supplementation: Early chick embryo model pilot study.
    Turgut U; Kazan S; Cakin H; Ozak A
    Int J Dev Neurosci; 2019 Nov; 78():45-48. PubMed ID: 31376429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproic acid disrupts the biomechanics of late spinal neural tube closure in mouse embryos.
    Hughes A; Greene NDE; Copp AJ; Galea GL
    Mech Dev; 2018 Feb; 149():20-26. PubMed ID: 29225143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate increases valproic acid-induced developmental toxicity, in particular neural tube defects in mice.
    Elmazar MM; Nau H
    Teratog Carcinog Mutagen; 1992; 12(5):203-10. PubMed ID: 1363493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect.
    Bojic U; Elmazar MM; Hauck RS; Nau H
    Chem Res Toxicol; 1996; 9(5):866-70. PubMed ID: 8828922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.